Hongzi Chen

Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

Steven M. Haffner, Andrew S. Greenberg, Wayde M. Weston et al. · Circulation · 2002 · 877 citations · Full text

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy

Dahong Yu, Susan J. Murdoch, Shamik Parikh et al. · Diabetes and Vascular Disease Research · 2006 · 22 citations · Full text

Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus

Jean‐Paul Albertini, Stephen McMorn, Hongzi Chen et al. · Atherosclerosis · 2007 · 20 citations

Metabolic Syndrome, Hypertension, Cardiovascular Disease +11

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

Greg Moeck, Leanne B. Gasink, Rodrigo E. Mendes et al. · Antimicrobial Agents and Chemotherapy · 2024 · 14 citations · Full text

Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?

Barry J. Goldstein, Alexander R. Cobitz, Linda M. Hand et al. · Current Medical Research and Opinion · 2003 · 12 citations